Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 11, 2014, Pages

  Schmidt, Julie Berg ^a   Gregersen, Nikolaj Ture ^a   Pedersen, Sue D ^a   Arentoft, Johanne L ^a   Ritz, Christian ^a   Schwartz, Thue W ^a   Holst, Jens Juul ^a   Astrup, Arne ^a   Sjödin, Anders ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Appetite; Energy expenditure; Energy intake; GLP 1; PYY

Indexed keywords

FATTY ACID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PEPTIDE YY [3-36]; INSULIN; PEPTIDE FRAGMENT; PEPTIDE YY; PEPTIDE YY (3 36);

ADULT; APPETITE; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENERGY EXPENDITURE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MALE; MEAL; MIDDLE AGED; NAUSEA; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; SATIETY; TASTE PREFERENCE; VITAL SIGN; ADOLESCENT; ANTHROPOMETRY; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ENERGY METABOLISM; FOOD PREFERENCE; GLUCOSE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; POSTPRANDIAL STATE; PYY; TASTE;

APPETITE; ENERGY EXPENDITURE; ENERGY INTAKE; GLP-1; PYY;

ADOLESCENT; ADULT; ANTHROPOMETRY; APPETITE; BLOOD GLUCOSE; BODY WEIGHT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FOOD PREFERENCES; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; NAUSEA; OVERWEIGHT; PEPTIDE FRAGMENTS; PEPTIDE YY; POSTPRANDIAL PERIOD; TASTE;

EID: 84901704935     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00569.2013     Document Type: Article

References (43)

1. Core Team R. R: A Language and Environment for Statiscial Computing. R Foundation for Statistical Computing. Vienna, Austria: ISBN 3-900051-07-0, 2012.
2. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC. Health benefits of gastric bypass surgery after 6 years. JAMA 308: 1122-1131, 2012.
3. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S, Savolainen MJ, Van GL. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36: 843-854, 2012.
4. Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci USA 94: 10455-10460, 1997.
5. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948, 2003.
6. Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450: 106-109, 2007.
7. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 64: 557-561, 1998.
8. Bjorklund P, Laurenius A, Een E, Olbers T, Lonroth H, Fandriks L. Is the Roux limb a determinant for meal size after gastric bypass surgery? Obes Surg 20: 1408-1414, 2010.
9. Brennan IM, Otto B, Feltrin KL, Meyer JH, Horowitz M, Feinle-Bisset C. Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men. Peptides 28: 607-611, 2007.
10. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719, 2001.
11. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623-1630, 2002.
12. De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6: 10-20, 2012.
13. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 14: 700-706, 2011.
14. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129: 1430-1436, 2005.
15. Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 13: 307-318, 2013.
16. Elia M, Livesey G. Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. World Rev Nutr Diet 70: 68-131, 1992.
17. Falken Y, Hellstrom PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96: 2227-2235, 2011.
18. Green SM, Delargy HJ, Joanes D, Blundell JE. A satiety quotient: a formulation to assess the satiating effect of food. Appetite 29: 291-304, 1997.
19. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 61: 40-44, 2013.
20. Harvey EJ, Arroyo K, Korner J, Inabnet WB. Hormone changes affecting energy homeostasis after metabolic surgery. Mt Sinai J Med 77: 446-465, 2010.
21. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
22. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery induced weight loss. Obesity (Silver Spring) 21: 1093-1103, 2013.
23. Jacobsen SH, Olesen SC, Dirksen C, Jorgensen NB, Bojsen-Moller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 22: 1084-1096, 2012.
24. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14: 1553-1561, 2006.
25. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 33: 786-795, 2009.
26. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3-8, 2006.
27. Miras AD, le Roux CW. Bariatric surgery and taste: novel mechanisms of weight loss. Curr Opin Gastroenterol 26: 140-145, 2010.
28. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146: 5120-5127, 2005.
29. O'Connor EA, Carlin AM. Lack of correlation between variation in small-volume gastric pouch size and weight loss after laparoscopic Rouxen-Y gastric bypass. Surg Obes Relat Dis 4: 399-403, 2008.
30. Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, Porter JL, Asplin J, Kuhn JA, Fordtran JS. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 92: 704-713, 2010.
31. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661, 1993.
32. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Court Gass M, Kern B, von FM, Beglinger C. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 22: 740-748, 2012.
33. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
34. Schellekens H, Dinan TG, Cryan JF. Lean mean fat reducing "ghrelin" machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology 58: 2-16, 2010.
35. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240-244, 2002.
36. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741-752, 2007.
37. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H, Ahlin S, Anveden A, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lonroth H, Narbro K, Naslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. JAMA 307: 56-65, 2012.
38. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose, and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292: E1062-E1068, 2007.
39. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 92: 810-817, 2010.
40. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756, 2005.
41. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389, 2001.
42. Zhang L, Nguyen AD, Lee IC, Yulyaningsih E, Riepler SJ, Stehrer B, Enriquez RF, Lin S, Shi YC, Baldock PA, Sainsbury A, Herzog H. NPY modulates PYY function in the regulation of energy balance and glucose homeostasis. Diabetes Obes Metab 14: 727-736, 2012.
43. Zoicas F, Droste M, Mayr BM, Buchfelder M, Schoefl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 168: 699-706, 2013.